Clinical Trials

70 enrolled

BreastOther neoplasm

Anatomic Stage IV Breast Cancer AJCC v8

NCT04071223 2026-03-18

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

134 enrolled

Carcinoma, Renal Cell

NCT03344211 2026-02-27

Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer

30 enrolled

Prostatic Neoplasms

NCT05133440 2026-01-21

A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones

12 enrolled

Prostatic Neoplasms

NCT05924672 2026-01-14

Efficacy of Ra-223 in PSMA PET Optimally Selected Patients

2 enrolled

Prostatic Neoplasms

NCT03361735 2025-05-02

Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

25 enrolled

Prostate Adenocarcinoma

NCT03304418 2025-04-30

RROPE

20 enrolled 14 charts

Prostate Cancer Metastatic to Bone

NCT03002220 2024-12-11

EXCAAPE

52 enrolled 15 charts

Prostatic Neoplasms

NCT02903160 2024-02-07

Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)

40 enrolled 18 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT02258451 2023-11-24

Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer

283 enrolled 22 charts

Breast Neoplasms

NCT00337155 2023-11-02

BAY88-8223, Dose Finding Study in Patients With HRPC

122 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT00667199 2023-04-19

BAY88-8223, Does Response Study in HRPC Patients

100 enrolled

Hormone Refractory Prostate Cancer

NCT02346526 2022-09-29

A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer

22 enrolled 14 charts

Prostatic Neoplasms

NCT02582749 2022-07-11

Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases

Phase 2 Terminated

16 enrolled 6 charts

Prostatic Neoplasms

NCT02366130 2021-10-07

Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer

45 enrolled 7 charts

Breast Neoplasms

NCT03062254 2021-09-21

Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 Therapy

14 enrolled

Prostatic Neoplasms

NCT02283749 2021-02-02

BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases

5 enrolled 7 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02199197 2020-10-30

Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer

49 enrolled 18 charts

Prostatic Neoplasms

NCT02258464 2020-08-10

Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer

Phase 2 Terminated

99 enrolled 18 charts

Breast Neoplasms

NCT02034552 2019-07-23

A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)

68 enrolled 17 charts

Prostatic Neoplasms

NCT02023697 2019-07-12

Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone

391 enrolled 53 charts

Prostatic Neoplasms

NCT02390934 2019-06-11

RAD-THYR

13 enrolled

Head & Neck

Thyroid Neoplasms

NCT02507570 2019-03-19

Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis

40 enrolled

Prostate Carcinoma Metastatic to the Bone

NCT01929655 2018-04-24

Japanese BAY88-8223 Monotherapy Phase II Study

49 enrolled

Prostatic Neoplasms

NCT02097303 2018-02-01

eRADicAte

36 enrolled 13 charts

Prostatic Neoplasms

NCT02656563 2016-10-14

RAND

Phase 2 Withdrawn

Prostatic Neoplasms

NCT02484339 2016-04-27

α-RT

Phase 2 Unknown

274 enrolled

Prostatic Neoplasms

NCT00459654 2014-06-25

A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer

64 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT01070485 2014-06-25

BAY88-8223, Alpharadin, Breast Cancer Patients With Bone Dominant Disease

23 enrolled